MCL
LYEL icon

MWG Caph Ltd’s Lyell Immunopharma LYEL Stock Holding History

MWG Caph Ltd’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$31M Buy
+1,008,116
New +$22.6M 42.88% 2

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

MWG Caph Ltd's LYEL Position: Q4 2025 in Review

MWG Caph Ltd opened a new position in Lyell Immunopharma (LYEL) in Q4 2025: 1,008,116 shares worth $31M. The stake represents 42.88% of the portfolio and ranks #2 among its holdings.

68 funds tracked by Wall St. Rank hold LYEL as of Q4 2025.

  • MWG Caph Ltd held 1,008,116 shares of Lyell Immunopharma worth $31M as of Q4 2025.
  • Lyell Immunopharma was a new MWG Caph Ltd position in Q4 2025.
  • Lyell Immunopharma made up 42.88% of MWG Caph Ltd's portfolio in Q4 2025, its #2 holding.
  • 68 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2025.

Based on MWG Caph Ltd's 13F filing for Q4 2025, filed 17 Feb 2026.